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Aims. Dysregulated expression of the endothelial nitric oxide synthase (eNOS) is observed in aortic aneurysms associated with
bicuspid aortic valve (BAV). We determined eNOS protein levels in various areas in ascending aortic aneurysms. Methods and
Results. Aneurysmal specimens were collected from 19 patients, 14 with BAV and 5 with tricuspid aortic valve (TAV). ENOS
protein levels were measured in the outer curve (convexity), the opposite side (concavity), the distal and above the sinotubular
junction (proximal) aneurysm. Cultured aortic cells were treated with NO synthesis inhibitor L-NAME and the amounts of 35
apoptosis-related proteins were determined. In patients with BAV, eNOS levels were signiﬁcantly lower in the proximal aorta than
in the concavity and distal aorta. ENOS protein levels were also lower in the convexity than in the concavity. While the convexity
and distal aorta showed similar eNOS protein levels in BAV and TAV patients, levels were higher in TAV proximal aorta. Inhibition
of NO synthesis in aneurysmal aortic cells by L-NAME led to a cytosolic increase in the levels of mitochondrial serine protease
HTRA2/Omi. Conclusion. ENOS protein levels were varied at diﬀerent areas of the aneurysmal aorta. The dysregulation of nitric
oxide can lead to an increase in proapoptotic HTRA2/Omi.
1.Introduction
Bicuspid aortic valve (BAV) is a common congenital cardiac
defect having a prevalence of 0.9% to 2%. It is associated
with stenosis, insuﬃciency, and ascending aortic aneurysms
[1]. The formation of ascending aortic aneurysms in BAV
patients seems to be linked to apoptosis of medial vascular
smooth muscle cells (VSMCs). Apoptosis was found to
be more frequent in the medial tissue of dilated aortas
a n dc u l t u r e dV S M C sd e r i v e df r o ma n e u r y s m a t i ca o r t a s .
Additionally cultured VSMCs derived from BAV dilated
aortas showed higher apoptosis rates than VSMCs from
control patients [2, 3].
The endothelial nitric oxide synthase (eNOS) is asso-
ciated with the development of BAV, and eNOS-produced
nitric oxide (NO) is also believed to play a role in aneurysm
formation. In 2000 Lee and colleagues showed that eNOS-
deﬁcient mice were predisposed to develop a BAV, whereas
Kuhlencordt et al. found a higher incidence of aortic
aneurysm in eNOS/Apolipoprotein E double-knockout mice
[4,5].AstudybyAicheretal.presentedasigniﬁcantdecrease
in eNOS protein amount in BAV aortic tissue compared
to TAV aortic tissue [6]. Expression and activity of eNOS
in aortic endothelial cells are controlled by hemodynamic
wall shear stress [7, 8]. Recent publications have indicated
that aortic wall shear stress diﬀers locally between BAV and
control patients when examined via magnetic resonance
imaging (MRI) [9, 10]. Furthermore we provided evidence
that VSMCs show a diﬀerent apoptotic behavior in the
concaveversustheconvexsideofthedilatedaorta.Inhibition2 Cardiology Research and Practice
Table 1: Patient characteristics.
Characteristics BAV
(n = 14)
TAV
(n = 5) P-value
Age (years) 51.9 ±12.25 9 .4 ±8.7 0.257
Sex (f/m) 3/11 1/4 0.5
BMI (kg/m2)2 7 .5 ±4.22 8 .6 ±8.2 0.333
Maximum sinus
diameter (mm) 38.3 ±5.1 53.0∗ —
STJ diameter (mm) 36.2 ±4.1 53.0∗ —
Tubular diameter (mm) 51.5 ±4.65 5 .4 ±7.3 0.444
Arch diameter (mm) 39.5 ±7.3n . a . —
Aortic stenosis 6/14
(42.9%) 0/5 (0%) 0.1
Aortic insuﬃciency 3/14
(21.4%)
5/5
(100%) 0.005
Combined
stenosis/insuﬃciency
5/14
(35.7%) 0/5 (0%) 0.2
BAV: bicuspid aortic valve; BMI: body mass index; f: female; m: male; n.a.:
not available; STJ: sinotubular junction; TAV: tricuspid aortic valve; ∗only
data from two patients were available, and therefore statistics were omitted.
of caspase-3 was shown to protect cultured cells derived
from the concavity of the aorta more signiﬁcantly than those
from the convexity [11]. Taken together, these results suggest
al o c a l l yd i ﬀerent behavior of medial cells in BAV aortic
tissue than in TAV aortic tissue [12]. This is particularly
interesting because it is known that eNOS-derived NO can
inhibitcaspasesviaS-nitrosylation[13],whichmightexplain
the observed diﬀerences in apoptosis between the diﬀerent
aortic areas. Therefore, we determined eNOS protein levels
atdiﬀerentaorticareasofaneurysmalBAVandTAVpatients.
We also determined the eﬀects of NO-synthesis inhibition
on apoptosis of primary human aortic endothelial cells
(HAECs) and human aortic VSMCs taken from tissue of a
BAV patient.
2. Methods
2.1. Sample Collection. The investigation conforms with the
principles outlined in the Declaration of Helsinki for use
of human tissue. The study protocol was approved by the
institutionalethicscommittee,andwritteninformedconsent
was obtained from all patients. Specimens of aortic wall
of 14 BAV and 5 TAV aneurysmal patients were collected
during surgery (patient characteristics are shown in Table 1).
The tissue was taken from 4 distinct areas of the aorta, the
concave side of the aorta (inner curves), the convex side of
the aorta (outer curves, the right anterolateral aspect), the
distal aneurysm (under the aortic arch), and the proximal
aneurysm(abovethesinotubularjunction),andimmediately
placed in liquid nitrogen. Cell lysate was prepared using
the Bio-Plex Cell Lysis Kit according to the manufacturer’s
instructions (BIO-Rad, Hamburg, Germany). Whole protein
concentration in the cell lysate was measured using the BCA
protein assay (Thermo Scientiﬁc, Rockford, USA).
2.2. Western Blot Analysis. The wells of NuPAGE 10% Bis-
Trisgels(Invitrogen,Darmstadt,Germany)wereloadedwith
20µg of cell lysate, and a denaturising SDS-PAGE was run
using the Xcell SureLock Mini-cell (Invitrogen, Darmstadt,
Germany) and appropriate buﬀers. The separated proteins
were transferred to a nitrocellulose membrane, which was
blocked with TBS-T containing 5% (v/w) BSA at 4◦C
overnight. The membrane was washed thrice in TBS-T
and incubated with primary antibody diluted in TBS-T
containing 5% BSA (v/w) for 1h. Then, the washing step
was repeated, and the membrane was treated with secondary
antibody in TBS-T containing 5% BSA (v/w) for 1h. NOS3
rabbit polyclonal antibody (sc-654) was used together with
bovine anti-rabbit IgG-AP (sc-2372) secondary antibody
(Santa Cruz Biotec, Heidelberg, Germany) to detect eNOS
p r o t e i n .T h em e m b r a n ew a sw a s h e dt h r i c ew i t hT B S - T
and thrice with TBS before protein bands were visualized
by incubation of the membrane in staining solution made
of 300µL NBT/BCIP stock solution (Roche, Mannheim,
Germany) and 15mL substrate buﬀer (0.1M Tris-HCl, pH
9.5, 0.1M NaCl, 0.05M MgCl2).
Band intensity was analyzed using the imageJ software.
To compare band intensity between diﬀerent blots, a calibra-
tor sample was run on every blot.
Both beta-actin (Novus Biologicals, Heford, Germany)
andGAPDH(SantaCruzBiotec,Heidelberg,Germany)were
tested as loading control. Both controls displayed a high
ﬂuctuation in band intensity. Therefore the initial loading
amount was used to normalize eNOS band intensity.
2.3. Cell Culture. Vascular smooth muscle cells (VSMCs)
were taken from the tunica media of a BAV patient. For
cell culture this sample was minced and treated with 0.26%
collagenase (250U/mL, Serva, Heidelberg, Germany) at
37◦C for about 3-4h. After centrifugation, the pellet was
resuspended in culture medium (TC199 with Earle’s salts
supplemented with 20% fetal bovine serum, 200U/mL
penicillin, 200µg/mL streptomycin) and incubated at 37◦C
in 5% CO2 air. After attachment of the tissue pieces 5mL
fresh medium were added. The monolayer culture was
passagedby standard trypsine dispersion and resuspended in
TC199 culture medium.
Primary human aortic endothelial cells (HAECs) were
purchased from Lonza and cultured in endothelial cell
growth medium-2 (Lonza, Cologne, Germany).
2.4. Transfection and Characterization of Human Aortic
VSMCs. HumanaorticVSMCsobtainedfromaﬁrstpassage
monolayer culture were plated in 25cm2 ﬂasks and allowed
toattachandgrowfor48huntiltheculturereachedapproxi-
mately80%conﬂuency.Thesubconﬂuentmusclecellculture
was then transfected with 5µg of pSV40-dN-plasmid DNA
as described previously [14, 15] using Eﬀectene kit (Qiagen;
Hilden, Germany). Culture supernatant containing trans-
fecting solution was removed after 1h. Cells were washed
with PBS and cultured in TC199 medium containing 20%
FCS and 2% (v/v) antibiotic solution. When cultures showed
focusformation,fociwereisolatedandsubculturedinTC199
culturemediumcontaining20%FCSand2%(v/v)antibiotic
solution. The population doubling time was measured as
described previously [14].Cardiology Research and Practice 3
For cell characterization, cytosolic proteins were extract-
ed and analyzed in western blot. In short cells were washed
with 1x PBS (4◦C), and 500µLo fc e l ll y s i sb u ﬀer (150mM
NaCl, 50mM TrisHCl, 0.5% deoxycholic acid, 1% NP-40)
containing 1x complete mini protease inhibitor (Roche,
Mannheim, Germany) were added. A cell scraper was used
to remove the VSMCs from the cell culture ﬂask, and the
suspension was incubated on a shaker on ice for 35min.
Subsequently the cell lysate was centrifuged at 14,200×ga n d
4◦C for 20min to collect the cytosolic protein fraction in
the supernatant. The whole protein amount was determined
using the BCA protein assay (Thermo Scientiﬁc, Rockford,
USA). Western blot analysis was performed as described
above. A smooth muscle alpha-actin primary antibody (Mab
1420;R&DSystems,Wiesbaden-Nordenstadt,Germany)was
used as a smooth muscle cell marker, and a von Willebrand
factor primary antibody (sc-53466; Santa Cruz, Heidelberg.
Germany) was used as marker for endothelium. Since
cells did contain smooth muscle alpha-actin but not von
Willebrand factor (data not shown) they were considered as
vascular smooth muscle cells (VSMCs).
2.5. L-NAME Treatment. VSMCs and HAECs were grown to
90% conﬂuency and then incubated in serum-free medium
for 24h. Afterwards cells were treated with 1mM of NO
synthase inhibitor L-NAME for one hour. The cytosolic
p r o t e i nf r a c t i o nw a se x t r a c t e da sd e s c r i b e da b o v e .
2.6. Quantiﬁcation of Apoptosis-Related Proteins. For quan-
tiﬁcation of 35 apoptosis-related proteins after L-NAME
treatment, 200µg of cytosolic protein were used in con-
junction with the proteome proﬁler array (R&D Systems,
Wiesbaden-Nordenstadt, Germany) according to the man-
ufacturer’s instructions. In short, the arrays were blocked
for 1h and then incubated with 200µg protein lysate at
4◦C over night. Afterwards the arrays were incubated with
biotinylated detection antibody cocktail (1:1000, R&D Sys-
tems, Wiesbaden-Nordenstadt, Germany) for one hour, and
antibiotin alkaline phosphatase conjugated secondary anti-
body (1:10,000, Sigma-aldrich, Munich, Germany) for 30
minutes. Protein spots were visualized with solution made
of 300µL NBT/BCIP stock solution (Roche, Mannheim,
Germany) and 15mL substrate buﬀer (0.1M Tris-HCl, pH
9.5, 0.1M NaCl, 0.05M MgCl2). Spot intensity was quan-
tiﬁed using the imagej software. The spots of the positive
control were used as calibrator. Data were taken from three
independent experiments with two replicates each.
2.7. Statistical Analysis. Statistical analysis was done with
SPSS and Excel/WinSTAT, and all data are displayed as
absolute numbers and relative percentages or as mean ±
standard deviation. Diﬀerences in eNOS protein expression
were tested with two-sided Mann—Whitney U-test for inde-
pendent variables (comparison between BAV and TAV areas)
or with Wilcoxon signed-rank test for dependent variables
(comparison between diﬀerent BAV or TAV areas). Diﬀer-
ences in apoptosis-related proteins after L-NAME treatment
were analysed with repeated measurement two-way ANOVA
to account for the two replicates on each apoptosis array.
Relative frequencies were compared using the ﬁsher exact
test. Signiﬁcant diﬀerences were assumed at P<0.05.
3. Results
3.1. Determination of eNOS Protein Levels in Diﬀerent Aortic
Areas. Aortic tissue was taken during aneurysmal replace-
ment from 14 patients with BAV and from 5 patients with
TAV. Patients with BAV tended to be younger, having a low
BMI, smaller aortic diameter with a higher percentage of
aortic stenosis and combined stenosis/insuﬃciency but a
signiﬁcantly lower percentage of aortic insuﬃciency (21.4%
versus 100%, P = 0.005). However, none of these charac-
teristics diﬀered signiﬁcantly along with gender distribution
and the percentageof aortic insuﬃciency (seeTable1).Sowe
assumed these patient groups to be comparable.
Protein levels of eNOS were quantiﬁed in the concavity,
distal aneurysm, convexity, and proximal aneurysm of these
BAV and TAV patients (Figure 1).
In TAV patients, eNOS protein level was least in the
concavity, at a medium level in the distal aorta and convex
side and highest in the proximal aneurysmal aorta. Nonethe-
less there was no signiﬁcant diﬀerence in eNOS amounts
between the TAV aneurysmal aortic areas. BAV patients on
the other hand featured the highest eNOS protein levels in
the concavity, while distal aneurysmal aorta and convexity
showed medium levels and the proximal aneurysmal aorta
showed low eNOS protein level. Several of these diﬀerences
proved to be signiﬁcant (concavity versus convexity, 93.14 ±
48.47versus59.67±46.03%ofcalibrator,P = 0.04;concavity
versusproximalaorta,93.14±48.47 versus43.00±53.38% of
calibrator, P = 0.02; distal versus proximal aorta, 61.2 ±31.8
versus 43.00 ±53.38% of calibrator, P = 0.03) (Figure 1(b)).
TheeNOSproteinamountintheTAVconcavesideofthe
aortawaslowerthanthatintheBAVconcavitybutthisdiﬀer-
ence was not signiﬁcant (49.57 ±23.6v e r s u s9 3 .14 ±48.47%
of calibrator, P = 0.07). In the distal aorta and the convex
aortic side there was little diﬀerence between TAV and BAV
eNOS protein amounts (distal aorta: 63.23 ± 31.99 versus
61.2±31.8% of calibrator, P = 0.96; convexity: 61.63±35.38
versus 59.67 ± 46.03% of calibrator, P = 0.75). However,
in the proximal aorta, eNOS levels were signiﬁcantly higher
in TAV patients than BAV patients (105.79 ± 75.11 versus
43.00 ± 53.38% of calibrator, P = 0.04) (Figure 1(c)).
3.2. Quantiﬁcation of Apoptosis-Related Proteins after Treat-
ment of VSMCs and HAECs with 1mM L-NAME. To deter-
mine the eﬀect a dysregulation of eNOS would have on
aortic cell apoptosis, we treated VSMCs originating from
aortic tissue and primary HAECs with 1mM of the speciﬁc
NO-synthase inhibitor L-NAME for one hour. Afterwards
35 apoptosis-related proteins were quantiﬁed using a pro-
teome proﬁler array for human apoptosis. In VSMCs most
apoptotic proteins increased in abundance, although only
HTRA2/Omi levels were signiﬁcantly elevated after L-NAME
treatment (P = 0.04, Figure 2).
Treatment with L-NAME resulted in little diﬀerence
in Bax, Bcl-2, and cleaved caspase-3 concentration. The
cytosolic amount of cytochrome c was slightly elevated4 Cardiology Research and Practice
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Figure 1: (a) Representative western blot of pooled cell lysate from 4 TAV and 4 BAV patients. 1: TAV concavity; 2: TAV distal aneurysm;
3: TAV convexity; 4: TAV proximal aneurysm; 5: BAV concavity; 6: BAV distal aneurysm; 7: BAV convexity; 8: BAV proximal aneurysm.
(b) The eNOS protein level ± SD in diﬀerent aortic areas was determined by densitometry. 1: TAV concavity; 2: TAV distal aneurysm; 3:
TAV convexity; 4: TAV proximal aneurysm; 5: BAV concavity; 6: BAV distal aneurysm; 7: BAV convexity; 8: BAV proximal aneurysm; P∗:
P<0.05; TAV: n = 5; BAV: n = 14. (c) eNOS protein levels in diﬀerent areas of TAV and BAV aneurysmal aorta. Mean levels of eNOS protein
amounts ± SD are given for each aortic area. Diﬀerences between eNOS protein levels of TAV (n = 5) and BAV (n = 14) in the proximal
aneurysmal aorta are signiﬁcant with P = 0.04.
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Figure 2: Change in concentration of apoptosis-related proteins
after treatment with L-NAME. Bars display the change in concen-
trationofBax,Bcl-2,cleavedcaspase3,cytochromec,HTRA2/Omi,
and the positive control after treatment of VSMCs with 1mM L-
NAME for 1h. ∗: P = 0.04.
(68.46±8.61versus76.39±8.48%ofcalibrator)althoughthis
diﬀerence was not signiﬁcant (P = 0.336). Cytosolic protein
levels of HTRA2/Omi on the other hand were signiﬁcantly
increased after inhibition of NO synthesis (63.1 ± 3.8v e r s u s
72.6 ± 4.2% of calibrator, P = 0.04). For changes in other
apoptosis-related proteins see Tables 2 and 3.H T R A 2 / O m i
is a mitochondrial serine protease, which is released into the
cytosol by proapoptotic members of the Bcl-2 family [15].
Here it contributes to apoptosis by cleavage of members
of the inhibitor of apoptosis (IAP) family, which otherwise
function as direct inhibitors of caspase-3, -7, and -9 [16, 17].
Therefore these results indicate some form of early apoptosis
in VSMCs after L-NAME treatment.
In HAECs no signiﬁcant changes in apoptosis-related
proteins could be observed after L-NAME treatment (Fig-
ure 3, see also Tables 2 and 3).
Bax, Bcl-2, cleaved caspase-3, and HTRA2/Omi did not
display any changes in cytosolic protein levels. Cytosolic
appearance of cytochrome c increased after L-NAME treat-
ment (62.37 ± 11.07 versus 84.29 ± 6.92% of calibrator) but
this diﬀerence was not signiﬁcant (P = 0.069).Cardiology Research and Practice 5
Table 2: Protein levels of 35 apoptosis-related proteins after treatment of VSMCs with 1mM L-NAME.
Protein Control average 1mM L-NAME average Change P
Bad 50.59 ± 8.08 54.73 ± 9.86 4.15 0.637
Bax 47.65 ± 14.26 50.98 ± 13.43 3.32 0.805
Bcl-2 31.37 ± 7.47 34.32 ± 5.04 2.95 0.633
Bcl-x 17.62 ± 4.92 19.02 ±6.20 1.40 0.780
Pro-Caspase 3 107.21 ± 20.89 109.96 ± 19.89 2.75 0.889
Cleaved Caspase 3 40.89 ± 12.79 43.35 ± 6.22 2.46 0.799
Catalase 93.40 ± 24.75 97.04 ± 25.26 3.63 0.880
clAP-1 39.80 ± 20.28 45.09 ± 20.87 5.28 0.792
clAP-2 16.72 ± 4.71 18.86 ± 5.27 2.15 0.630
Claspin 40.49 ± 6.13 43.37 ± 6.39 2.89 0.618
Clusterin 22.70 ± 6.30 27.93 ± 7.19 5.23 0.437
Cytochrome c 68.46 ± 8.61 76.39 ± 8.48 7.93 0.336
TRAIL R1/DR4 40.74 ± 6.48 46.36 ± 3.04 5.62 0.241
TRAIL R2/DR5 66.06 ± 16.01 77.34 ± 6.60 11.28 0.363
FADD 64.20 ± 13.56 71.59 ± 4.95 7.39 0.467
Fas/TNFSF6 66.16 ± 23.27 68.26 ± 13.45 2.10 0.904
HIF-1a 29.40 ± 16.62 41.97 ± 15.61 12.57 0.436
HO-1/HMOX1/HSP32 27.06 ± 14.68 35.64 ± 12.58 8.58 0.526
HO-2/HMOX2 38.85 ± 14.23 49.90 ± 18.08 11.04 0.497
HSP27 33.21 ± 7.16 38.64 ± 9.88 5.43 0.528
HSP60 65.84 ± 11.85 70.83 ± 7.05 4.99 0.545
HSP70 66.75 ± 13.76 64.40 ± 5.59 −2.35 0.801
HTRA2/Omi 63.09 ±3.83 72.57 ± 4.18 9.48 0.038∗
Livin 14.08 ± 2.52 18.83 ± 5.12 4.75 0.223
PON2 28.81 ± 5.92 31.30 ± 5.53 2.49 0.651
p21/CIP1/CDNK1A 27.93 ± 9.01 38.74 ± 9.16 10.81 0.259
p27/Kip1 16.75 ± 6.04 21.34 ± 2.89 4.59 0.345
Phospho-p53 (S15) 82.25 ± 19.34 88.18 ± 11.03 5.93 0.696
Phospho-p53 (S46) 64.83 ± 18.94 71.42 ± 20.27 6.59 0.729
Phospho-p53 (S392) 64.02 ± 28.92 75.33 ± 22.81 11.31 0.659
Phospho-Rad17 (S635) 11.71 ± 2.21 18.72 ± 5.65 7.01 0.129
SMAC/Diablo 56.47 ± 11.12 59.84 ± 9.98 3.36 0.742
Survivin 57.52 ± 23.63 61.96 ± 19.33 4.44 0.831
TNF RI/TNFRSF1A 18.18 ± 4.27 22.05 ± 1.64 3.87 0.210
XIAP 49.96 ± 5.39 56.28 ± 3.45 6.32 0.149
Allvaluesareinpercentofthecalibrator(positivecontrol).Thechangeisgiveninpercentpointsofthecalibrator.Thedatawereacquiredinthreeindependent
experiments. ∗: P < 0.05.
4. Discussion
The bicuspid aortic valve (BAV) is often associated with
ascending aortic aneurysms. Ascending aortic aneurysms are
marked by a pathologic dilatation of the aorta to the at
least 1.5-fold diameter. The enzyme endothelial nitric oxide
synthase (eNOS) catalyses the conversion of L-arginine to L-
citrulline and nitric oxide (NO), which serves as a signaling
molecule in the cardiovascular system [18, 19]. NO is known
to mediate several vasoprotective properties, like inhibition
of vascular smooth muscle cells (VSMCs) and proliferation
and maintaining of endothelial function [20, 21].
Evidence for a connection between eNOS and BAV was
given when Aicher et al. compared eNOS protein expression
in patients with TAV and patients with BAV. They showed
a downregulation of eNOS in the proximal aorta of BAV
patients compared to TAV patients [6]. Our results demon-
strate a varying expression of the eNOS protein in diﬀerent
areas of the aneurysmal aorta of BAV and TAV patients.
While eNOS levels are indeed lower in the BAV proximal
aortathaninitsTAVcounterpart,theBAVconcavityfeatures
a higher eNOS expression than the TAV concavity, although
this diﬀerence was not signiﬁcant in our experiments (P =
0.07). The eNOS protein amount in the convexity and the
distal aorta seems to be on equal levels in BAV and TAV.
The upregulation of eNOS mRNA expression by ﬂuid
shear stress is well established [7]. Recently Barker et al.
quantiﬁed shear stress in BAV and control patients by phase6 Cardiology Research and Practice
Table 3: Protein levels of 35 apoptosis-related proteins after treatment of HAECss with 1mM L-NAME.
Protein Control average 1mM L-NAME average Change P
Bad 62.83 ± 4.88 66.76 ± 12.67 3.92 0.661
Bax 52.36 ± 16.36 54.62 ± 12.14 2.26 0.878
Bcl-2 35.77 ± 6.52 40.28 ± 4.95 4.51 0.373
Bcl-x 20.18 ± 5.18 17.03 ± 3.48 −3.16 0.410
Pro-Caspase 3 92.79 ± 10.67 89.73 ± 9.55 −3.06 0.756
Cleaved Caspase 3 29.29 ± 7.84 23.81 ± 3.32 −5.48 0.392
Catalase 58.39 ± 12.35 55.87 ± 6.19 −2.53 0.803
clAP-1 35.59 ± 9.16 27.73 ± 16.97 −7.87 0.560
clAP-2 15.76 ± 3.62 16.86 ± 5.57 1.10 0.813
Claspin 18.69 ± 2.87 18.00 ± 2.51 −0.69 0.745
Clusterin 35.62 ± 11.69 39.72 ± 4.57 4.10 0.660
Cytochrome c 62.37 ± 11.07 84.29 ± 6.92 21.92 0.069
TRAIL R1/DR4 56.01 ± 3.15 57.91 ± 12.80 1.91 0.833
TRAIL R2/DR5 88.48 ± 1.03 91.83 ± 8.18 3.35 0.516
FADD 72.14 ± 8.15 72.21 ± 7.40 0.07 0.989
Fas/TNFSF6 41.58 ± 7.37 34.54 ± 9.89 −7.04 0.303
HIF-1a 28.35 ± 7.46 26.07 ± 6.38 −2.29 0.735
HO-1/HMOX1/HSP32 30.43 ± 6.38 26.90 ± 12.93 −3.53 0.728
HO-2/HMOX2 35.86 ± 1.94 34.72 ± 11.64 −1.15 0.887
HSP27 41.67 ± 9.25 44.93 ± 11.15 3.26 0.699
HSP60 62.68 ± 8.65 70.54 ± 22.29 7.87 0.640
HSP70 65.35 ± 7.42 69.88 ± 17.35 4.53 0.727
HTRA2/Omi 78.98 ± 5.64 84.13 ± 9.00 5.15 0.482
Livin 12.39 ± 2.85 17.58 ± 6.45 5.18 0.315
PON2 41.23 ± 2.47 44.50 ± 12.63 3.27 0.711
p21/CIP1/CDNK1A 30.05 ± 11.24 35.52 ± 9.31 5.47 0.611
p27/Kip1 30.42 ± 3.67 29.70 ± 4.48 −0.73 0.777
Phospho-p53 (S15) 22.92 ± 6.58 25.48 ± 6.03 2.56 0.680
Phospho-p53 (S46) 8.84 ± 4.14 9.08 ± 2.81 0.24 0.948
Phospho-p53 (S392) 4.06 ± 2.69 5.01 ± 6.63 0.95 0.844
Phospho-Rad17 (S635) 12.24 ± 3.83 13.16 ± 9.86 0.92 0.900
SMAC/Diablo 63.31 ± 14.25 63.90 ± 12.04 0.59 0.956
Survivin 23.28 ± 1.48 21.28 ± 3.96 −2.00 0.443
TNF RI/TNFRSF1A 27.19 ± 3.24 25.24 ± 4.74 −1.95 0.599
XIAP 53.37 ± 7.73 51.67 ± 3.93 −1.70 0.769
Allvaluesareinpercentofthecalibrator(positivecontrol).Thechangeisgiveninpercentpointsofthecalibrator.Thedatawereacquiredinthreeindependent
experiments.
contrast MRI and thereby revealed a signiﬁcant diﬀerence
in aortic shear stress distribution between the groups
[10]. Moreover, they found the hemodynamic forces to be
signiﬁcantly higher in the concavity of BAV patients than in
control patients, while wall shear stress in the convexity was
equal in both groups. These ﬁndings suggest an upregulation
of eNOS in the BAV concavity by ﬂuid shear stress which
coincidences with our data. It is reasonable to assume that
the altered valve morphology in BAV results in a diﬀerent
distribution of aortic wall shear stress and therefore leads to
al o c a l l yd i ﬀerent eNOS expression compared to TAV.
Apoptosis of vascular smooth muscle cells (VSMCs)
seems to account for the formation of aneurysm in BAV
[2,3,22].InarecentstudyweprovidedevidencethatVSMCs
show a diﬀerent behaviour in respect to apoptosis in the
concave versus the convex sites in BAV ascending aortic
aneurysm [11]. We found that the inhibition of caspase 3
leads to an increased protection against apoptosis in the BAV
concavity compared with the convexity. The detection of
a signiﬁcantly higher eNOS protein expression in the BAV
concavity than in the BAV convexity appears to be consistent
with these earlier results, since nitric oxide generated by
eNOS is known to inhibit apoptosis by s-nitrosylation of cas-
pases [13]. Therefore it seems that an elevated eNOS expres-
sion in the BAV concavity can contribute to an increased
protection against VSMC apoptosis in this aortic area.
To analyze the eﬀect a dysregulation of eNOS could have
on VSMC and HAEC apoptosis, we treated VSMCs whichCardiology Research and Practice 7
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Figure 3: Change in concentration of apoptosis-related proteins
after treatment with L-NAME. Bars display the change in concen-
trationofBax,Bcl-2,cleavedcaspase3,cytochromec,HTRA2/Omi,
and the positive control after treatment of HAECs with 1mM
L-NAME for 1h.
originated from aortic tissue, as well as primary HAECs
with 1mM of the NO synthase inhibitor L-NAME. Of note,
L-NAME does not speciﬁcally inhibit eNOS but all NO
synthases. Although eNOS is the primary source of NO in
the aorta, other NO synthases are known to be active in
VSMC under certain conditions [23]. Therefore the eﬀect
of L-NAME treatment cannot solely be attributed to eNOS
inhibition. We are also aware that eNOS is mainly expressed
in endothelial cells. However, it was shown that VSMCs do
express eNOS and that the produced NO is physiologically
relevant [24, 25]. Inhibition of NO synthesis in VSMC
resulted in an increase in cytosolic HTRA2/Omi proteins.
HTRA2/Omi is a mitochondrial serine protease, which ini-
tiates apoptosis if released into the cytosol [26]. Treatment
of HAECs with L-NAME did not account for any changes
in cytosolic HTRA2/Omi levels but the cytosolic amount
of cytochrome c increased after NO synthase inhibition
although the diﬀerence was not signiﬁcant (P = 0.069). The
increased presence of mitochondrial proteins in the cytosol
after L-NAME treatment indicates an inhibitory eﬀect of
eNOS produced NO on the intrinsic apoptosis pathway. This
pathway, opposed to the death receptor triggered extrinsic
pathway, is activated by proapoptotic Bcl-2 proteins, which
cause mitochondrial outer-membrane permeabilization and
thus cause a release of mitochondrial cytochrome c into
the cytosol. Here cytochrome c facilitates assembly of the
apoptosome, which activates procaspase-9 and therefore
initiates caspase cascades [26, 27]. We detected neither in
VSMCs nor in HAECs an increase in the Bax/Bcl-2 ratio
after treatment with L-NAME. This is astonishing, since an
increase in the ratio of Bax to Bcl-2 normally indicates an
activation of the intrinsic apoptosis pathway [28].
NO is reported to have pro- and antiapoptotic eﬀects
depending on its concentration, at which physiological con-
centrations act antiapoptotic [29, 30]. A study by Liu et al.
showed that excessive amounts of NO can lead to an increase
in HTRA2/Omi release from mitochondria and endothelial
cell apoptosis by formation of peroxynitrite [31]. Here we
show that a reduction of physiological NO concentration by
inhibition of NO synthesis can result in cytosolic accumu-
lation of HTRA2/Omi. This presumably leads to apoptosis
of VSMCs. The locally diﬀerent eNOS expression we found
in BAV patients can account for a lower NO concentration
in certain aortic areas and therefore lead to upregulation of
HTRA2/Omi which might initiate apoptosis in VSMCs.
We are aware that our sample number, especially for TAV
patients, is limited and ourdata display a high standard devi-
ation. However, Barker et al. also discovered a high standard
deviation when they determined aortic wall shear stress in
BAVpatients[10].Henceitcouldbehypothesizedthatahigh
standard deviation in eNOS expression is due to a high stan-
dard deviation of aortic wall shear stress which inﬂuences
expression of eNOS. Fluctuation in shear stress between
BAV patients might be due to the morphology of the aortic
valve, as BAV is known to feature heterogeneous phenotypes
depending on the morphological type of BAV [32–34].
In summary, we showed a locally variable eNOS protein
expression in BAV aortic aneurysms than in TAV aortic
aneurysms. In addition, we showed a cytosolic accumulation
of the proapoptotic serine protease HTRA2/Omi after treat-
ment of VSMCs with L-NAME. Taken together, these results
indicate a locally diﬀerent eNOS protein expression, which
is probably caused by variations in aortic wall shear stress
between BAV and TAV aortic aneurysm patients, which in
turn might be caused by diﬀerences in BAV and TAV valve
morphology. We conclude that eNOS dysregulation can lead
to a dysregulation of NO in certain areas of the aorta, which
canleadtoVSMCapoptosismediatedbyHTRA2/Omi.Thus
the low eNOS protein expression in the BAV proximal aorta
may confer susceptibility to aortic aneurysm formation.
Authors’ Contribution
Both authors have contributed equally to this paper.
Conﬂict of Interests
The authors declare that they have no conﬂict of interests.
Acknowledgments
The authors would like to thank Werner Wosniok for his
advice on statistical analysis.
References
[1] S. C. Siu and C. K. Silversides, “Bicuspid aortic valve disease,”
Journal of the American College of Cardiology, vol. 55, no. 25,
pp. 2789–2800, 2010.
[2] D. Bonderman, E. Gharehbaghi-Schnell, G. Wollenek, G.
Maurer, H. Baumgartner, and I. M. Lang, “Mechanisms
underlying aortic dilatation in congenital aortic valve malfor-
mation,” Circulation, vol. 99, no. 16, pp. 2138–2143, 1999.
[3] M. Nataatmadja, M. West, J. West et al., “Abnormal extracel-
lular matrix protein transport associated with increased apop-
tosis of vascular smooth muscle cells in Marfan syndrome and
bicuspid aortic valve thoracic aortic aneurysm,” Circulation,
vol. 108, supplement 1, pp. II329–II334, 2003.8 Cardiology Research and Practice
[ 4 ]T .C .L e e ,Y .D .Z h a o ,D .W .C o u r t m a n ,a n dD .J .S t e w a r t ,
“Abnormal aortic valve development in mice lacking endothe-
lial nitric oxide synthase,” Circulation, vol. 101, no. 20, pp.
2345–2348, 2000.
[ 5 ]P .J .K u h l e n c o r d t ,R .G y u r k o ,F .H a ne ta l . ,“ A c c e l e r a t e d
atherosclerosis, aortic aneurysm formation, and ischemic
heart disease in apolipoprotein E/endothelial nitric oxide syn-
thase double-knockout mice,” Circulation, vol. 104, no. 4, pp.
448–454, 2001.
[ 6 ]D .A i c h e r ,C .U r b i c h ,A .Z e i h e r ,S .D i m m e l e r ,a n dH .J .
Schafers, “Endothelial nitric oxide synthase in bicuspid aortic
valve disease,” Annals of Thoracic Surgery,v o l .8 3 ,n o .4 ,p p .
1290–1294, 2007.
[7] V. Ranjan, Z. Xiao, and S. L. Diamond, “Constitutive NOS
expression in cultured endothelial cells is elevated by ﬂuid
shear stress,” American Journal of Physiology, vol. 269, no. 2,
pp. H550–H555, 1995.
[8] Y. C. Boo and H. Jo, “Flow-dependent regulation of endothe-
lial nitric oxide synthase: role of protein kinases,” American
Journal of Physiology, vol. 285, no. 3, pp. C499–C508, 2003.
[9] E. Weigang, F. A. Kari, F. Beyersdorf et al., “Flow-sensitive
four-dimensional magnetic resonance imaging: ﬂow patterns
in ascending aortic aneurysms,” European Journal of Cardio-
thoracic Surgery, vol. 34, no. 1, pp. 11–16, 2008.
[10] A. J. Barker, C. Lanning, and R. Shandas, “Quantiﬁcation
of hemodynamic wall shear stress in patients with bicuspid
aortic valve using phase-contrast MRI,” Annals of Biomedical
Engineering, vol. 38, no. 3, pp. 788–800, 2010.
[11] S. A. Mohamed, M. Misfeld, T. Hanke et al., “Inhibition of
caspase-3 diﬀerentially aﬀects vascular smooth muscle cell
apoptosisintheconcaveversusconvexaorticsitesinascending
aneurysms with a bicuspid aortic valve,” Annals of Anatomy,
vol. 192, no. 3, pp. 145–150, 2010.
[12] S. A. Mohamed and H. H. Sievers, “Ascending aneurysms in
bicuspid aortic valve,” in Diagnosis and Treatment of Abdom-
inal and Thoracic Aortic Aneurysms Including the Ascending
Aorta and the Aortic Arch, R. T. Grundmann, Ed., pp. 161–174,
InTech, Rijeka, Croatia, 2011.
[13] J. Li, T. R. Billiar, R. V. Talanian, and Y. M. Kim, “Nitric
oxide reversibly inhibits seven members of the caspase family
via S-nitrosylation,” Biochemical and Biophysical Research
Communications, vol. 240, no. 2, pp. 419–424, 1997.
[14] B. Kazmierczak, S. Bartnitzke, M. Hartl, and J. Bullerdiek, “In
vitro transformation by the SV40 “early region” of cells from
a human benign salivary gland tumor with a 12q13→p15
rearrangement,” Cytogenetics and Cell Genetics, vol. 53, no. 1,
pp. 37–39, 1990.
[15] G. Belge, B. Kazmierczak, K. Meyer-Bolte, S. Bartnitzke, and
J. Bullerdiek, “Expression of SV40 T-antigen in lipoma cells
with a chromosomal translocation t(3;12) is not suﬃcient for
directimmortalization,”CellBiologyInternationalReports,vol.
16, no. 4, pp. 339–347, 1992.
[16] G. van Loo, M. van Gurp, B. Depuydt et al., “The serine
protease Omi/HtrA2 is released from mitochondria during
apoptosis. Omi interacts with caspase-inhibitor XIAP and
induces enhanced caspase activity,” Cell Death and Diﬀeren-
tiation, vol. 9, no. 1, pp. 20–26, 2002.
[17] Q. L. Deveraux and J. C. Reed, “IAP family proteins—
suppressors of apoptosis,” Genes & Development, vol. 13, no.
3, pp. 239–252, 1999.
[18] W. C. Sessa, “eNos at a glance,” Journal of Cell Science, vol. 117,
no. 12, pp. 2427–2429, 2004.
[19] D. M. Dudzinski, J. Igarashi, D. Greif, and T. Michel, “The
regulation and pharmacology of endothelial nitric oxide syn-
thase,” Annual Review of Pharmacology and Toxicology, vol. 46,
pp. 235–276, 2006.
[20] M. T. Gewaltig and G. Kojda, “Vasoprotection by nitric
oxide: mechanisms and therapeutic potential,” Cardiovascular
Research, vol. 55, no. 2, pp. 250–260, 2002.
[21] P. L. Huang, “eNOS, metabolic syndrome and cardiovascular
disease,” Trends in Endocrinology & Metabolism,v o l .2 0 ,n o .6 ,
pp. 295–302, 2009.
[22] F. X. Schmid, K. Bielenberg, A. Schneider, A. Haussler, A.
Keyser, and D. Birnbaum, “Ascending aortic aneurysm asso-
ciated with bicuspid and tricuspid aortic valve: involvement
and clinical relevance of smooth muscle cell apoptosis and
expression of cell death-initiating proteins,” European Journal
of Cardio-thoracic Surgery, vol. 23, no. 4, pp. 537–543, 2003.
[23] M. E. Ward, M. Toporsian, J. A. Scott et al., “Hypoxia induces
afunctionallysigniﬁcantandtranslationallyeﬃcientneuronal
NO synthase mRNA variant,” Journal of Clinical Investigation,
vol. 115, no. 11, pp. 3128–3139, 2005.
[24] I. B. Buchwalow, T. Podzuweit, V. E. Samoilova et al., “An in
situ evidence for autocrine function of NO in the vasculature,”
Nitric Oxide, vol. 10, no. 4, pp. 203–212, 2004.
[25] I. B. Buchwalow, S. Cacanyiova, J. Neumann, V. E. Samoilova,
W.Boecker,andF.Kristek,“Theroleofarterialsmoothmuscle
in vasorelaxation,” Biochemical and Biophysical Research Com-
munications, vol. 377, no. 2, pp. 504–507, 2008.
[26] M. S. Bhuiyan and K. Fukunaga, “Activation of HtrA2, a mito-
chondrial serine protease mediates apoptosis: current knowl-
edge on HtrA2 mediated myocardial ischemia/reperfusion
injury,” Cardiovascular Therapeutics, vol. 26, no. 3, pp. 224–
232, 2008.
[27] J.E.ChipukandD.R.Green,“Doinducersofapoptosistrigger
caspase-independent cell death?” Nature Reviews Molecular
Cell Biology, vol. 6, no. 3, pp. 268–275, 2005.
[28] S. A. Mohamed, T. Hanke, A. W. Erasmi et al., “Mitochondrial
DNA deletions and the aging heart,” Experimental Gerontol-
ogy, vol. 41, no. 5, pp. 508–517, 2006.
[29] P. S. Brookes, E. P. Salinas, K. Darley-Usmar et al.,
“Concentration-dependent eﬀects of nitric oxide on mito-
chondrial permeability transition and cytochrome c release,”
Journal of Biological Chemistry, vol. 275, no. 27, pp. 20474–
20479, 2000.
[30] H. M. Razavi, J. A. Hamilton, and Q. Feng, “Modulation of
apoptosis by nitric oxide: implications in myocardial ischemia
and heart failure,” Pharmacology and Therapeutics, vol. 106,
no. 2, pp. 147–162, 2005.
[31] Q. B. Liu, L. L. Liu, Y. M. Lu et al., “The induction of reactive
oxygen species and loss of mitochondrial Omi/HtrA2 is asso-
ciated with S-nitrosoglutathione-induced apoptosis in human
endothelial cells,” Toxicology and Applied Pharmacology, vol.
244, no. 3, pp. 374–384, 2010.
[32] W.C.Roberts,“Thecongenitallybicuspidaorticvalve.Astudy
of 85 autopsy cases,” The American Journal of Cardiology, vol.
26, no. 1, pp. 72–83, 1970.
[33] H.H.SieversandC.Schmidtke,“Aclassiﬁcationsystemforthe
bicuspid aortic valve from 304 surgical specimens,” Journal of
Thoracic and Cardiovascular Surgery, vol. 133, no. 5, pp. 1226–
1233, 2007.
[34] B. M. Schaefer, M. B. Lewin, K. K. Stout et al., “The bicuspid
aortic valve: an integrated phenotypic classiﬁcation of leaﬂet
morphology and aortic root shape,” Heart, vol. 94, no. 12, pp.
1634–1638, 2008.